Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19 Neoplasms 3 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Castration-Resistant Prostate Cancer 2 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Adenocarcinoma 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Follicular 1 Colorectal Neoplasms 1 Castrate Sensitive Prostate Cancer 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Bulbo-Spinal Atrophy, X-Linked 1 Bites and Stings 1 Advanced Prostate Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 3 Leucovorin 3 Fluorouracil 3 Capecitabine 3 zolbetuximab 2 trastuzumab deruxtecan 2 pembrolizumab 2 Ramucirumab 2 Paclitaxel 2 repotrectinib 1 lenvatinib 1 fludarabine 1 enzalutamide 1 durvalumab 1 darolutamide 1 aldesleukin 1 Vinorelbine 1 Radiosurgery 1 Radiation 1 Prednisone 1 Prednisolone 1 Positron-Emission Tomography 1 Pemetrexed 1 PF06821497 1 Nivolumab 1 Negative-Pressure Wound Therapy 1 Microscopy, Confocal 1 MORAb-202 1 Irinotecan 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × enzalutamide × 30 days × Clear all

NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡